Pancreatic Cancer

Positive Results in Initial GVAX Vaccine Trial Reported

Published in Vaccine Weekly, June 7th, 2000

Cell Genesys, Inc. (CEGE), Foster City, California, reported prolongation of disease-free survival in a Phase I trial of a pancreatic cancer vaccine in patients who received the vaccine following surgery and adjuvant radiation and chemotherapy.

In a trial in 14 patients conducted at the Johns Hopkins Oncology Center, three of eight patients receiving the two highest doses of the vaccine are alive and free of disease for more than two years following treatment, while the six patients receiving the two lowest doses have relapsed. Additionally, all three of the patients with prolonged disease-free survival have biopsy-proven vaccine-induced antitumor immunity, a finding...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-06-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry